The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction.
about
The role of NMDA receptor antagonists in nicotine tolerance, sensitization, and physical dependence: a preclinical review.Differential role of the nitric oxide pathway on delta(9)-THC-induced central nervous system effects in the mouse.Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration.Pathophysiology of opioid tolerance and clinical approach to the opioid-tolerant patient.Drug dependence as a disorder of neural plasticity: focus on dopamine and glutamate.The nonmedical use of ketamine, part two: A review of problem use and dependence.Sensitive and rapid HPLC method for determination of memantine in human plasma using OPA derivatization and fluorescence detection: application to pharmacokinetic studies.Dextromethorphan differentially affects opioid antinociception in rats.The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity.The beta-lactam antibiotic, ceftriaxone, attenuates morphine-evoked hyperthermia in rats.Evaluation of the reinforcing and subjective effects of heroin in combination with dextromethorphan and quinidinePeriaqueductal gray neuroplasticity following chronic morphine varies with age: role of oxidative stress.A survey of acute and chronic heroin dependence in ten inbred mouse strains: evidence of genetic correlation with morphine dependence.Novel medications to treat addictive disordersA Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawalOpioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.Memantine and dizocilpine interactions with antinociceptive or discriminative stimulus effects of morphine in rats after acute or chronic treatment with morphine.Glutamate mechanisms underlying opiate memoriesNMDARs in neurological diseases: a potential therapeutic target.Nitroxidergic modulation of behavioural, cardiovascular and immune responses, and brain NADPH diaphorase activity upon morphine tolerance/dependence in rats.Effects of the Persian Carum copticum fruit extracts on morphine withdrawal syndrome in mice.A Validated Stability-indicating Reverse Phase HPLC Assay Method for the Determination of Memantine Hydrochloride Drug Substance with UV-Detection Using Precolumn Derivatization Technique.Imidazoline receptor antisera-selected/Nischarin regulates the effect of agmatine on the development of morphine dependence.Antinociceptive effect of clavulanic acid and its preventive activity against development of morphine tolerance and dependence in animal models.Opioid tolerance in neonates: a state-of-the-art review.Opioids are non-competitive inhibitors of nitric oxide synthase in T47D human breast cancer cells.Effect of post-trial L-NAME administration on cocaine sensitization.Lactoferrin elicits opioid-mediated antinociception without development of tolerance: central nNOS-1 set off duty?Attenuation of tolerance to opioid-induced antinociception by idazoxan and other I2-ligands.Phencyclidine, excitatory amino acids, psychiatry and drug abuse: Historical perspectives on clinical-laboratory interactions.
P2860
Q30491487-26A26D9E-83C1-4A21-B318-A63D5B087031Q31900735-CA8BE51B-4EED-4365-B8C0-6B82136BE9E2Q33830017-5B55B1CD-FB1D-48B1-A6B4-4B83A77B4B11Q34040562-D3C43F96-3409-4EA3-99B8-FAB015A6DB85Q34273699-0E714D4C-27A3-4CF4-9956-05CF8AC3045AQ34321128-6DF9880A-7F29-4C00-9D25-AA905747F026Q34430243-3659C124-27CF-4A19-8148-A749FA3C1B08Q35048603-EB6B71F2-ABAE-4789-8D57-B38CCC610ACAQ35164063-4FE6D5A1-4F30-42A0-90D6-9AE2120D75B9Q36094287-3015948E-CB8A-47CF-ADC0-2D5178208894Q36100597-5126031E-7EA6-4014-8B19-8D59ADED0F4EQ36374150-257378F6-D709-48A6-A16C-B152CF4D4CF3Q36768752-605DA3CB-720A-406E-AD8C-1567AFFED310Q37029633-D16E8833-C02A-4E86-A91A-CAA147E99ED5Q37036723-3416DEB8-FC82-4736-827A-0D60A8C63355Q37065797-90319B86-131F-4DD1-ACA9-9A18E1FEE241Q37183549-1FC82409-7FE7-47D2-A59E-085D2EF159B1Q38040996-72B1AFD4-1A44-4F3D-ACAA-BD231DDABFA8Q38232734-45B64C45-F7A9-4A3C-9931-DD0715EE16ECQ40740343-84A35B16-AC5E-4742-A7C3-093356858623Q41542628-768576AB-8C73-4D67-BB9A-402FFC569356Q42136504-019026EE-B02B-479F-B95F-8DE3E1FD9663Q42495434-87861A72-2A41-4BE8-BAFE-653778F345F7Q43063827-3D9B4854-B082-45CE-A269-5FB09FF74D44Q43069472-D73ACF27-9679-48E4-AE70-259A0EC66785Q43722386-418C5AE0-B0F3-4DF1-AEA3-CB40BD65ADECQ43800411-213EA8A4-F66B-4AB0-A772-6462FA63FB4AQ44342186-7EC59278-6405-4F6C-B847-006F42CC0B27Q44352404-7AF0B5BD-AA04-49C0-9652-0E28504F7F74Q51540705-4BC9E6AD-D963-4F44-AB16-FC7F189AE42B
P2860
The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction.
description
1995 nî lūn-bûn
@nan
1995 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
The effects of NMDA receptor a ...... t issues for opiate addiction.
@ast
The effects of NMDA receptor a ...... t issues for opiate addiction.
@en
The effects of NMDA receptor a ...... t issues for opiate addiction.
@nl
type
label
The effects of NMDA receptor a ...... t issues for opiate addiction.
@ast
The effects of NMDA receptor a ...... t issues for opiate addiction.
@en
The effects of NMDA receptor a ...... t issues for opiate addiction.
@nl
prefLabel
The effects of NMDA receptor a ...... t issues for opiate addiction.
@ast
The effects of NMDA receptor a ...... t issues for opiate addiction.
@en
The effects of NMDA receptor a ...... t issues for opiate addiction.
@nl
P2093
P1476
The effects of NMDA receptor a ...... t issues for opiate addiction.
@en
P2093
P2888
P304
P356
10.1016/0893-133X(95)00140-9
P407
P577
1995-12-01T00:00:00Z
P6179
1023395170